A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab plus Pertuzumab plus a Taxane Following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and
safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta
(pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and a taxane as
adjuvant therapy in patients with HER2-positive primary invasive breast cancer. Following
surgery and anthracycline-based chemotherapy, patients will receive either Kadcyla 3.6 mg/kg
and Perjeta 420 mg intravenously (iv) every three weeks or Herceptin 6 mg/kg iv every three
weeks in combination with Perjeta and a taxane. Anticipated time on HER2 targeted study
treatment is up to 1 year.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.